Molecularmd
Molecularmd is recorded as a service provider in 14 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 14 of 14 trials · Latest update first
A Phase 3, Randomized, Open-Label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combined with Chemotherapy Versus Investigator’s Choice of TKI Combined with Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) (POLARIS-1)
Sponsor Ascentage Pharma Group Inc.
- Start (EU)
- Latest update
- Estimated end
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
Sponsor Kite Pharma Inc.
- Start (EU)
- Latest update
- Estimated end
A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2)
Sponsor Ascentage Pharma Group Inc.
- Start (EU)
- Latest update
- Estimated end
A Long-Term Follow-Up Study for Participants Previously Treated with KYV-101 (KYSA-4)
Sponsor Kyverna Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Open-Label, Randomized, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Primary and Secondary Progressive Multiple Sclerosis (KYSA-7)
Sponsor Kyverna Therapeutics Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS
Sponsor Celgene Corp.
- Start (EU)
- Latest update
- Estimated end
A PHASE 2, OPEN-LABEL, SINGLE-ARM, MULTICOHORT, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF JCAR017 IN ADULT SUBJECTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL) (Transcend FL)
Sponsor Celgene Corp.
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3, Open-Label, Randomized, Controlled, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, Versus Ongoing Standard-Of-Care Immunosuppressive Therapy in Patients with Generalized Myasthenia Gravis (KYSA-6)
Sponsor Kyverna Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU 285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy
Sponsor Blueprint Medicines Corp.
- Start (EU)
- Latest update
- Estimated end
An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-23)
Sponsor Kite Pharma Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
I4C-MC-JTBB: A Randomized, Controlled Phase 2 Study Evaluating LY2875358 plus Erlotinib versus Erlotinib as First-Line Treatment in Metastatic NSLC Patients with Activating EGFR Mutations Who Have Disease Control after an 8-Week Lead-In Treatment with Erlotinib
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
A Phase II Study of Dasatinib Therapy in Children and Adolescents with Ph+ Leukemias Resistant or Intolerant to Imatinib.
Sponsor Bristol Myers Squibb International Corporation
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Molecularmd?
The 2026-10-09 snapshot links Molecularmd to 14 distinct CTIS trials. Recorded services include Laboratory services, Biomarker analysis, CAR T cell PK (PVS/VCN), DNA Mutation Analysis, among 8 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Molecularmd?
The most frequently recorded therapeutic areas are Haematological Malignancies, Immunology, Neurology, Nephrology. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Molecularmd conducted?
The linked trials record locations in 18 countries, including Germany, Spain, France, Italy, Austria. These are trial locations, not confirmed office locations or countries where Molecularmd delivered services.
What can this page tell me about Molecularmd's trial experience?
Browse 14 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Molecularmd. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Molecularmd Corp.